Keywords: Gilead. Tibotec, Johnson & Johnson, Cobicistat, Prezista, HIV, EMtriva, Combination drugs
Gilead to develop combo cobicistat and Prezista AIDS drug with J&J unit Tibotec
Article | 29 June 2011
US biotech firm Gilead Sciences (Nasdaq: GILD) has entered into a license agreement with Tibotec Pharmaceuticals, an Ireland-based subsidiary of ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
